Glycogen Synthase Kinase-3β Inhibition Preserves Hematopoietic Stem Cell Activity and Inhibits Leukemic Cell Growth
Authors:
Open Access
- 6 March 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 26 (5) , 1288-1297
Abstract
Ex vivo expansion of cord blood cells generally results in reduced stem cell activity in vivo. Glycogen synthase kinase-3β (GSK-3β) regulates the degradation of β-catenin, a critical regulator of hematopoietic stem cells (HSCs). Here we show that GSK-3β inhibition activates β-catenin in cord blood CD34+ cells and upregulates β-catenin transcriptional targets c-myc and HoxB4, both known to regulate HSC self-renewal. GSK-3β inhibition resulted in delayed ex vivo expansion of CD34+ cells, yet enhanced the preservation of stem cell activity as tested in long-term culture with bone marrow stroma. Delayed cell cycling, reduced apoptosis, and increased adherence of hematopoietic progenitor cells to bone marrow stroma were observed in these long-term cultures treated with GSK-3β inhibitor. This improved adherence to stroma was mediated via upregulation of CXCR4. In addition, GSK-3β inhibition preserved severe combined immunodeficiency (SCID) repopulating cells as tested in the nonobese diabetic/SCID mouse model. Our data suggest the involvement of GSK-3β inhibition in the preservation of HSC and their interaction with the bone marrow environment. Methods for the inhibition of GSK-3β may be developed for clinical ex vivo expansion of HSC for transplantation. In addition, GSK-3β inhibition suppressed leukemic cell growth via the induction of apoptosis mediated by the downregulation of survivin. Modulators of GSK-3β may increase the range of novel drugs that specifically kill leukemic cells while sparing normal stem cells. Disclosure of potential conflicts of interest is found at the end of this article.Keywords
This publication has 27 references indexed in Scilit:
- Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic lymphocytic leukemia B cellsBlood, 2007
- Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signalingExperimental Hematology, 2007
- Bcl-2 expression and apoptosis in the regulation of hematopoietic stem cellsLeukemia & Lymphoma, 2007
- Induction of cell death in adult T-cell leukemia cells by a novel IκB kinase inhibitorLeukemia, 2006
- A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemiaOncogene, 2006
- A retroviral library genetic screen identifies IRF-2 as an inhibitor of N-ras-induced growth suppression in leukemic cellsOncogene, 2005
- Mutant N-ras preferentially drives human CD34+ hematopoietic progenitor cells into myeloid differentiation and proliferation both in vitro and in the NOD/SCID mouseExperimental Hematology, 2004
- Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitorNature Medicine, 2003
- Induced p21WAF1 expression acts to reverse myc myelomonocytic cell transformationCancer Gene Therapy, 2000
- Regulation of β-Catenin Signaling in the Wnt PathwayBiochemical and Biophysical Research Communications, 2000